Common Technical Data for Dossier Preparation I Export Documents Checklist

By -
Full registration dossier consists of 5 modules:

1. Module 1: ADMINISTRATIVE INFORMATION
1.1 Table of contents.
1.2. Application form.
1.3. Summary of product characteristics, labelling and instructions for medical use:
1.3.1. Summary of product characteristics.
1.3.2. Labelling.
1.3.3. Instructions for medical use.
1.3.4. Mock-ups and specimens.
1.3.5. Summary of product characteristics already approved in the manufacturer/applicant-country.
1.4. Information about the independent experts:
1.4.1. Information about the quality expert.
1.4.2. Information about the pre-clinical expert.
1.4.3. Information about clinical expert.
1.5 Specific requirements for different types of applications.
Annex to Module 1. Environmental risk assessment

MODULE 2: CTD SUMMARY
2.1. Table of contents of Modules 2 – 5.
2.2. Introduction.
2.3. Quality overall summary.
2.4. Pre-clinical overview:
2.5. Clinical overview
2.6. Pre-clinical summary
2.6.1. Pharmacology written summary.
2.6.2. Pharmacology tabulated summary.
2.6.3. Pharmacokinetics written summary.
2.6.4. Pharmacokinetics tabulated summary.
2.6.5. Toxicology written summary.
2.6.6. Toxicology tabulated summary.
2.7. Clinical summary:
2.7.1. Summary of biopharmaceutical studies and associated analytical methods.
2.7.2. Summary of clinical pharmacology studies.
2.7.3. Summary of clinical efficacy.
2.7.4. Summary of clinical safety.
2.7.5. Literature references.
2.7.6 Synopses of individual studies.


MODULE 3: QUALITY.
CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL INFORMATION FOR MEDICINAL PRODUCTS CONTAINING CHEMICAL AND/OR BIOLOGICAL ACTIVE SUBSTANCES
3.1. Table of contents.
3.2. Basic data.
3.2.S. Active substance(s).
3.2.S.1. General information:
3.2.S.1.1. Nomenclature.
3.2.S.1.2. Structure.
3.2.S.1.3. General properties
3.2.S.2. Manufacture of active substance(-s):
3.2.S.2.1. Manufacturer(s).
3.2.S.2.2. Description of manufacturing process and process controls.
3.2.S.2.3. Control of materials.
3.2.S.2.4. Controls of critical steps and intermediates.
3.2.S.2.5. Process validation and/or evaluation.
3.2.S.2.6. Manufacturing process development.
3.2.S.3. Characterization of active substance(-s).
3.2.S.3.1. Elucidation of structure and other characteristics.
3.2.S.3.2. Impurities.
3.2.S.4. Control of active substance(s).
3.2.S.4.1. Specification.
3.2.S.4.2. Analytical procedures.
3.2.S.4.3. Validation of analytical procedures.
3.2.S.4.4. Batch analyses.
3.2.S.4.5. Justification of specification.
3.2.S.5. Reference standards or materials.
3.2.S.6. Container/closure system.
3.2.S.7. Stability:
3.2.S.7.1. Stability summary and conclusions.
3.2.S.7.2. Post-approval stability protocol and stability commitment.
3.2.S.7.3. Stability data.
3.2.P. Finished medicinal product:
3.2.P.1. Description and composition of the medicinal product.
3.2.P.2. Pharmaceutical development:
3.2.P.2.1. Composition of the medicinal products.
3.2.P.2.1.1. Active substance(s).
3.2.P.2.1.2. Excipients.
3.2.P.2.2. Medicinal product.
3.2.P.2.2.1. Formulation development.
3.2.P.2.2.2. Overages.
3.2.P.2.2.3. Physicochemical and biological properties.
3.2.P.2.3. Manufacturing process development.
3.2.P.2.4. Container/closure system.
3.2.P.2.5. Microbiological attributes.
3.2.P.2.6. Compatibility.
3.2.P.3. Manufacture of the medicinal product:
3.2.P.3.1. Manufacturer(s)
3.2.P.3.2. Batch formula
3.2.P.3.3. Description of manufacturing process and process controls.
3.2.P.3.4. Controls of critical steps and intermediates.
3.2.P.3.5. Process validation and/or evaluation.
3.2.P.4. Control of excipients:
3.2.P.4.1. Specifications.
3.2.P.4.2. Analytical procedures.
3.2.P.4.3. Validation of analytical procedures.
3.2.P.4.4. Justification of specifications.
3.2.P.4.5. Excipients of human or animal origin.
3.2.P.4.6. Novel excipients.
3.2.P.5. Control of medicinal product:
3.2.P.5.1. Specification(s).
3.2.P.5.2. Analytical procedures.
3.2.P.5.3. Validation of analytical procedures.
3.2.P.5.4. Batch analyses.
3.2.P.5.5. Characterization of impurities.
3.2.P.5.6. Justification of specification(s).
3.2.P.6. Reference standards and materials.
3.2.P.7.Container/closure system.
3.2.P.8. Stability:
3.2.P.8.1. Stability summary and conclusion
3.2.P.8.2. Post-approval stability protocol and stability commitment
3.2.P.8.3. Stability data
3.2.A. Appendices:
3.2.A.1. Facilities and equipment. 
3.2.A.2. Adventitious agents safety evaluation.
3.2.A.3. Novel excipients.
3.2.R. Additional information.
3.3. Literature references.

Module 4: PRE-CLINICAL STUDY REPORTS
4.1. Table of contents.
4.2. Study reports.
4.2.1. Pharmacology:
4.2.1.1. Primary pharmacodynamics.
4.2.1.2. Secondary pharmacodynamics.
4.2.1.3. Safety pharmacology.
4.2.1.4. Pharmacodynamic interactions.
4.2.2. Pharmacokinetics:
4.2.2.1. Analytical methods and validation reports.
4.2.2.2. Absorption.
4.2.2.3. Distribution.
4.2.2.4. Metabolism.
4.2.2.5. Excretion.
4.2.2.6. Pharmacokinetic interactions (pre-clinical).
4.2.2.7. Other pharmacokinetic studies.
4.2.3. Toxicology:
4.2.3.1. Single-dose toxicity.
4.2.3.2. Repeated dose toxicity.
4.2.3.3. Genotoxicity
4.2.3.4. Carcinogenicity.
4.2.3.5. Reproductive and developmental toxicity.
4.2.3.6. Local tolerance.
4.2.3.7. Other toxicity studies.
4.3. Literature references.

MODULE 5: CLINICAL STUDY REPORTS
5.1. Table of contents.
5.2. Tabular listing of all clinical studies.
5.3. Clinical study reports:
5.3.1. Reports of biopharmaceutical studies.
5.3.2. Reports of studies pertinent to pharmacokinetics using human biomaterials.
5.3.3. Reports of human pharmacokinetic studies.
5.3.4. Reports of human pharmacodynamic studies
5.3.5. Reports of efficacy and safety studies.
5.3.6. Reports of post-registration experience.
5.3.7. Samples of case reports forms and individual patient listings.
5.4. Literature references.

Popular posts from this blog

Cleaning Validation | Campaign Cleaning Validation (CCV)

By -
Image
When the product demand does not allow for a complete clean up after each batch, a campaign cleaning validation must be conducted.   A back to back cleaning is performed between batches in a campaign, and a complete cleaning at the end of a campaign. Sampling of the equipment is performed after the last batch in a campaign, and all test results must meet predetermined acceptance criteria as per campaign cleaning validation protocol.   Samples for residual active may be taken after back to back cleanings where possible, for information only . Microbiology samples may be taken after back to back cleanings in a campaign to ensure that there is no excessive microbial growth on the equipment.
Read more

Western blot | troubleshooting | samples turn yellow and precipitate

By -
Image
Why western Blot samples turn yellow and precipitate? Sample appears to be acidic. Bromophenol blue in the loading buffer turns to yellow at acidic pH (below 3). Try to adjust the pH by adding NaOH [ 1 ].  Reason for that is proteins may be getting degraded due to heat exposure. One researcher had the same problem and so instead of keeping samples at 95 ° c  he started warming at 60-65 °  C. So anyone can try it out and as [ 1 ] said check the pH as well of the loading dye [ 2] .  Heating a sample also changes pH. An altered pH is not only responsible to turn the sample color yellow, but may also precipitate the proteins. Keeping SDS containing samples in ice is another common mistake to see this precipitation [ 3 ].  Another researcher said that he has got to do more with the total protein concentration in the lysate. He faced the same problem of precipitation upon denaturation at 100 ° c . He added 1/10th volume of 10% SDS and then boiled. Protein did not precipitate. T
Read more

Blending | Effective Sampling During Process Validation | Optimize Sampling Location

By -
Image
Important of sampling during blending: Sampling plays a great role in achieving the accurate results of analysis. Sampling must and procedure must be defined in validation protocols and training should be provided to the concerned staff before the validation activities start. Samples are representative of the whole batch. So it should be handled and weight carefully because segregation may occur during weighing and transpiration. Sample quantity should not be more than the required and whole mass sample should be used in the analysis. Fig: Blending Machine Sampling for blend: Blends are tested for their homogeneity. Homogeneity of the blend is critical for the quality of the final product. The sample should be taken from at least 10 locations in the blender. The sampling location should be selected according to the difficulty of the blending. Ares of poor blending must be covered in sampling. Corners and discharged point must have sampling location.
Read more